Added to YB: 2026-02-04
Pitch date: 2026-02-02
SANA [bullish]
Sana Biotechnology, Inc.
-9.8%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States.
Market Cap
$1.0B
Pitch Price
$4.59
Price Target
40.00 (+866%)
Dividend
N/A
EV/EBITDA
-6.92
P/E
-4.00
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Show full summary:
Sana Biotechnology: Now or Never...
SANA (new position): Gene-edited 'hypoimmune' stem cell therapy for T1D shows 1-year insulin independence vs typical 1-month transplant survival. SC451 entering Phase 1 trials 2026. Superior tech to VRTX but behind in trials. $1.4B market cap vs potential $25-40 acquisition target. High risk/reward play.
Read full article (5 min)